Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
INVA similar filings
- 14 Feb 08 Results of Operations and Financial Condition
- 1 Feb 08 Departure of Directors or Principal Officers
- 23 Jan 08 Theravance Announces Pricing of Convertible Subordinated
- 15 Jan 08 Other Events
- 11 Jan 08 Other Events
- 7 Jan 08 Departure of Directors or Principal Officers
- 5 Dec 07 Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-acquired Pneumonia Program
Filing view
External links
Exhibit 99.1
® 1 ‘698 ICS Phase 2 QD Dose-Ranging Study Improved Lung Function vs. Placebo Mean change from baseline in trough FEV1 (L) following 8 weeks' treatment - 0.05 0.10 0.15 0.20 0.25 0.30 0.35 Placebo 200mcg QD 400mcg QD No adverse effect on cortisol excretion |